The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

We have in-house Spravato therapy for persisting depression and may refer you to explore TMS therapy, Stellate Ganglion Block, Ketamine Infusion and integration therapy at our Westmont flagship.

We offer a variety of treatment modalities including medication management, Spravato, Ketamine, and TMS. My background of more than 15 years of experience in medicine and psychiatry offers a ...

Ketamine can trigger symptoms similar to those of schizophrenia, but it isn’t known to cause the disorder itself. Ketamine is gaining attention for its potential to treat depression and other ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient clinic ...

Esketamine, an anaesthetic derived from Ketamine, was approved for use in treating patients with Major Depressive Disorder (MDD) by the Health Sciences Authority (HSA) back in Oct. 2020.

A researcher is working on apps that he hopes will be able to identify signs of depression. The programs take and analyze photos of the eyes and face while someone uses the smartphone for other ...